Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dare Bioscience

2.04
0.0000
Volume:79.59K
Turnover:161.99K
Market Cap:27.50M
PE:-10.46
High:2.05
Open:2.04
Low:2.02
Close:2.04
52wk High:9.19
52wk Low:1.83
Shares:13.48M
Float Shares:13.34M
Volume Ratio:0.93
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1951
EPS(LYR):-0.4770
ROE:-994.69%
ROA:-63.13%
PB:-2.16
PE(LYR):-4.28

Loading ...

Dare Bioscience Inc. Receives Nasdaq Panel Approval for Modified Compliance Plan; Faces Crucial July 31, 2025 Deadline to Avoid Delisting

Reuters
·
Jun 25

Press Release: Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Dow Jones
·
Jun 13

BUZZ-Australia's Lynas Rare Earths gains on signing rare earths deal with Malaysian co

Reuters
·
May 30

Dare Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

BRIEF-Daré Bioscience Reports First Quarter 2025 Financial Results And Provides Company Update

Reuters
·
May 14

Dare Bioscience Q1 EPS $(0.50) Up From $(0.81) YoY, Sales $25.43K Up From $9.30K YoY

Benzinga
·
May 14

Daré Bioscience Reports Q1 2025 Financial Results; Expects Revenue Generation in Q4 2025 as Part of Expanded Commercial Strategy

Reuters
·
May 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 13

Dare Bioscience Inc expected to post a loss of 58 cents a share - Earnings Preview

Reuters
·
May 10

Dare Bioscience Inc expected to post a loss of 58 cents a share - Earnings Preview

Reuters
·
May 02

Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation

GlobeNewswire
·
Apr 23

Investors Await Key Employment, Manufacturing Data as US Futures Mixed in Thursday's Premarket

MT Newswires Live
·
Apr 17

Dare Bioscience to present on expanded business strategy at Jones Conference

TIPRANKS
·
Apr 07

Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year

GlobeNewswire
·
Apr 07

Q4 2024 Dare Bioscience Inc Earnings Call

Thomson Reuters StreetEvents
·
Apr 01

Dare Bioscience Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 01

Dare Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 01

BRIEF-Daré Bioscience Reports Full Year 2024 Financial Results

Reuters
·
Apr 01

Dare Bioscience expects to start recording revenue, cash flow in Q425

TIPRANKS
·
Apr 01

Press Release: Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Dow Jones
·
Apr 01